← All trials
NCT04059471
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 12, 2019
- Primary completion
- Dec 31, 2021
- Completion date
- Apr 30, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 900
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of OxfordLead sponsor
- Medical Research Council-UVRI Uganda Research Unit on AIDSCollaborator
- University of OxfordStudy director
- University of OxfordReponsible party - principal investigator
- Wellcome TrustCollaborator
- Institut PasteurCollaborator
- EpicentreCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.